← All trials
NCT05579119
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 6, 2022
- Primary completion
- Jul 31, 2023
- Completion date
- Jul 31, 2024
- First posted
- Oct 13, 2022
- Last posted
- Oct 13, 2022
- Enrollment
- 68
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Instituto Mexicano del Seguro SocialLead sponsor
- National Polytechnic Institute, MexicoCollaborator
- Centro Medico Nacional La Raza, IMSSOverall official - principal investigator
- Centro Medico Nacional La Raza, IMSSReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.